2,116 results match your criteria International Journal of Clinical Oncology[Journal]


Oncologic and reproductive outcomes of cystectomy as a fertility-sparing treatment for early-stage epithelial ovarian cancer.

Int J Clin Oncol 2019 Feb 15. Epub 2019 Feb 15.

Department of Obstetrics and Gynecology, Graduate School of Medicine, Nagoya University, Truma-cho 65, Showa-ku, 466-8550, Nagoya, Japan.

Background: Fertility-sparing surgery (FSS) has mainly been chosen for young women with ovarian-confined/well-differentiated epithelial ovarian cancer (EOC). In general, FSS consists of at least conservation of contralateral ovary and the uterus with a staging surgery. However, information on the clinical outcome in women who underwent cystectomy as a fertility-preserving option is lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01416-yDOI Listing
February 2019

Adjuvant therapy in renal cell carcinoma: the perspective of urologists.

Int J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

Department of Urology, Ludwig Maximilian University, Marchioninistr. 15, 81377, Munich, Germany.

Background: Until recently, there was no approved adjuvant therapy (AT) for renal cell carcinoma (RCC) unless sunitinib was approved in the US. We evaluated clinical opinion and estimated use regarding different treatment options and patient selection of AT in RCC patients based on current scientific data and individual experience in Germany.

Methods: We conducted an anonymous survey during a national urology conference in 01/2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01398-xDOI Listing
February 2019

Use of direct oral anti-coagulants for the treatment of venous thromboembolism in patients with advanced cancer: a prospective observational study.

Int J Clin Oncol 2019 Feb 12. Epub 2019 Feb 12.

Clinical Research Promotion Unit, Clinical Research Support Center, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.

Background: The efficacy of direct oral anti-coagulants (DOACs) for the treatment of venous thromboembolism (VTE) in Japanese patients with advanced cancer is largely unknown.

Methods: This prospective single-center observational study enrolled Japanese patients with unresectable advanced cancer who started DOAC treatment for new-onset VTE between December 2015 and May 2018. Patients were followed for 3 months to evaluate bleeding and VTE recurrences. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-019-01415-z
Publisher Site
http://dx.doi.org/10.1007/s10147-019-01415-zDOI Listing
February 2019
2 Reads

Survivin rs9904341 polymorphism significantly increased the risk of cancer: evidence from an updated meta-analysis of case-control studies.

Int J Clin Oncol 2019 Feb 12. Epub 2019 Feb 12.

Genetics of Non-communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.

Aims: Survivin, a member of inhibitor of apoptosis protein family, is involved in the regulation of cell cycle and apoptosis. Several studies inspected the association between survivin polymorphisms and the risk of various cancers, but the findings remain controversial. We conducted a meta-analysis intending to certify the association between survivin polymorphisms and cancer risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01408-yDOI Listing
February 2019
2.170 Impact Factor

Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience.

Int J Clin Oncol 2019 Feb 12. Epub 2019 Feb 12.

Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.

Objective: To evaluate the efficacy and prognosis of repeated treatment on patients with recurrent endometrial cancer (EC) after complete remission for primary fertility-preserving therapy.

Materials And Methods: We performed a retrospective study of patients with presumed stage IA endometrial cancer who had recurrence after achieving complete remission by fertility-preserving management at the Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, from January 2003 to April 2018. For each patient, medical records and pathology reports were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01404-2DOI Listing
February 2019
2.170 Impact Factor

Saddle pulmonary embolism and in-hospital mortality in patients with cancer.

Int J Clin Oncol 2019 Feb 12. Epub 2019 Feb 12.

College of Pharmacy, Medical University of South Carolina, 280 Calhoun Street, QE213C MSC140, Charleston, SC, 29425, USA.

Purpose: Saddle pulmonary embolism (PE) has been associated with an increased risk of 1 year mortality when compared to non-saddle PE among patients with cancer. We sought to evaluate the association between saddle PE and in-hospital outcomes among patients with comorbid cancer.

Methods: The 2013 and 2014 United States National Inpatient Sample was used to identify adult patients hospitalized for acute PE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01406-0DOI Listing
February 2019
1 Read

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.

Int J Clin Oncol 2019 Feb 11. Epub 2019 Feb 11.

Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Background: Alternative anti-androgen therapy (AAT) with flutamide after combined androgen blockade (CAB) therapy with bicalutamide for metastatic prostate cancer is common. However, no studies have compared enzalutamide without AAT with enzalutamide after AAT with flutamide as treatment for castration-resistant prostate cancer (CRPC). We aimed to compare the efficacies of flutamide and enzalutamide for CRPC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01413-1DOI Listing
February 2019

Patterns of lymph node metastasis and the management of neck dissection for parotid carcinomas: a single-institute experience.

Int J Clin Oncol 2019 Feb 9. Epub 2019 Feb 9.

Department of Otorhinolaryngology-Head and Neck Surgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.

Background: There is no consensus about the indications and range of neck dissection in patients who have parotid carcinoma, with elective neck dissection for cN0 disease being particularly controversial.

Methods: This study retrospectively reviewed 185 patients with newly diagnosed parotid carcinoma who were treated at our department between September 1999 and August 2018.

Results: 50 of the 185 patients had lymph node metastasis, including 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01411-3DOI Listing
February 2019

Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer.

Int J Clin Oncol 2019 Feb 9. Epub 2019 Feb 9.

Department of Urology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan.

Background: To compare the prognostic outcomes between first-generation antiandrogen (FGA) and novel androgen-receptor-axis-targeted agent (ARATA) as first-line therapy in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Methods: This study retrospectively included a total of 103 consecutive nmCRPC patients consisting of 47 (45.6%) and 56 (54. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01412-2DOI Listing
February 2019
1 Read

Optimal treatment strategy for rectal cancer based on the risk factors for recurrence patterns.

Int J Clin Oncol 2019 Feb 5. Epub 2019 Feb 5.

Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Background: For rectal cancer, multimodality therapeutic approach is necessary to prevent local recurrence and distant metastasis. However, the efficacy of additional treatments, such as neoadjuvant chemoradiotherapy (nCRT), neoadjuvant chemotherapy (NAC), and lateral pelvic lymph node dissection (LPLND), has not been scrutinized.

Methods: Recurrence patterns were categorized into local recurrence and distant metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01400-6DOI Listing
February 2019
3 Reads

Early tumor shrinkage after first-line medical treatment of metastatic colorectal cancer: a meta-analysis.

Int J Clin Oncol 2019 Feb 4. Epub 2019 Feb 4.

Department of Oncology, Ospedale Civile di Sanremo, Via G. Borea n. 56, 18038, Sanremo, Imperia, Italy.

Background: Early tumor shrinkage (ETS) is a response-related endpoint of clinical trials of chemotherapy (CHT) of patients with metastatic colorectal cancer (mCRC). It identifies a dimensional reduction of tumor size by at least 20-30% after 6-8 weeks of CHT.

Methods: A literature search of randomized trials of systemic treatment including CHT with or without antiangiogenics or anti-EGFR inhibitors in patients with mCRC has been conducted, and studies reporting the results of the relationship of ETS with overall survival (OS) and progression-free survival (PFS) were selected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01405-1DOI Listing
February 2019

Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy.

Int J Clin Oncol 2019 Feb 1. Epub 2019 Feb 1.

Division of Urology, Department of Surgery, Saint Louis University, 3635 Vista Ave, 3rd Floor Desloge Towers, St. Louis, MO, 63110, USA.

Background: Squamous cell carcinoma (SCC) of the bladder is a rare, aggressive malignancy. Unlike urothelial cell carcinoma, SCC is resistant to chemotherapy and guidelines recommend radical cystectomy (RC) without neoadjuvant chemotherapy (NAC). We aimed to evaluate the current management and survival of patients with invasive SCC treated with or without NAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01409-xDOI Listing
February 2019
1 Read

Radiotherapy alone as a possible de-intensified treatment for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma.

Int J Clin Oncol 2019 Jan 29. Epub 2019 Jan 29.

Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Background: Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) is defined by p16 positivity and/or HPV DNA positivity. Because survival of patients with HPV-related OPSCC after chemoradiotherapy is favorable, a de-intensified treatment is expected to lead to less morbidity while maintaining low mortality. The association of tumor p16 and HPV DNA status with survival after radiotherapy alone remains unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01394-1DOI Listing
January 2019

STAT3 rs4796793 contributes to lung cancer risk and clinical outcomes of platinum-based chemotherapy.

Int J Clin Oncol 2019 Jan 28. Epub 2019 Jan 28.

Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Background: Signal transducer and activator of transcription (STAT) 3 plays a vital role in carcinogenesis and drug response. Platinum-based chemotherapy is the first-line treatment for lung cancer patients, especially those in advanced stages. In the present study, we investigated the association of STAT3 polymorphism rs4796793 with lung cancer susceptibility, platinum-based chemotherapy response, and toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-01386-7DOI Listing
January 2019
2.170 Impact Factor

Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.

Int J Clin Oncol 2019 Jan 17. Epub 2019 Jan 17.

Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.

Background: Locally advanced squamous cell carcinoma of the head and neck (LASCCHN) is usually treated with cisplatin (CDDP)-based chemoradiotherapy, except when patients are elderly or have renal, cardiac, or neurogenic dysfunction. This study compared the safety and efficacy of concurrent carboplatin (CBDCA) to cetuximab (Cmab) plus radiotherapy (RT) in patients ineligible for CDDP treatment.

Methods: We retrospectively analyzed LASCCHN patients who received CBDCA plus RT (n = 29) or Cmab plus RT (n = 18) due to ineligibility for CDDP treatment at two Japanese institutions between August 2006 and December 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-01392-9DOI Listing
January 2019
2 Reads

Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.

Int J Clin Oncol 2019 Feb 5;24(2):141-152. Epub 2019 Jan 5.

Department of Colorectal Surgery, Changhai Hospital, 168 Changhai Road, Shanghai, 200433, China.

Background: Simultaneous detection of multiple molecular biomarkers is helpful in the prediction of treatment response and prognosis for colorectal cancer (CRC) patients.

Methods: A 22-gene panel consisting of 103 hotspot regions was utilized in the formalin-fixed paraffin-embedded (FFPE) tissue samples of 207 CRC patients, using the next-generation sequencing (NGS)-based multiplex PCR technique. Those 22 genes included AKT1, ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA, PTEN, SMAD4, STK11, and TP53. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-1377-1DOI Listing
February 2019
3 Reads
2.170 Impact Factor

Does postoperative prophylactic irradiation of para-aortic lymph nodes reduce the risk of recurrence in uterine cervical cancer with positive pelvic lymph nodes?

Int J Clin Oncol 2019 Jan 5. Epub 2019 Jan 5.

Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsuruma-cho 65, Showa-ku, Nagoya, 466-8550, Japan.

Background: In cervical cancer, para-aortic lymph nodes are common sites of metastasis. The purpose of the study was to evaluate the clinical benefits of prophylactic irradiation as postoperative therapy.

Methods: A retrospective cohort study was conducted during 2001-2015 at a single institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-1376-2DOI Listing
January 2019
1 Read

mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.

Int J Clin Oncol 2019 Jan 5. Epub 2019 Jan 5.

Tokyo Medical and Dental University, Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.

Background: The TRICC0808 trial is a phase II multi-institutional trial that investigated the efficacy of preoperative mFOLFOX6 + bevacizumab (BV) therapy for liver-only metastasis that is unsuitable for upfront resection. The R0 resection rate in the efficacy analysis has been reported to be 44.4%, and the final analysis for survival was conducted (data fixation on February 16, 2015). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-01393-8
Publisher Site
http://dx.doi.org/10.1007/s10147-018-01393-8DOI Listing
January 2019
1 Read

Clinical factors associated with the therapeutic outcome of chemotherapy in very elderly cancer patients.

Int J Clin Oncol 2019 Jan 3. Epub 2019 Jan 3.

Division of Internal Medicine, Department of Medicine, Higashi-Sapporo Hospital, 3-3-7-35, Higashi Sapporo, Shiroishi-ku, Sapporo, Hokkaido, 003-8585, Japan.

Background: The purpose of this study was to detect background factors that might be associated with the therapeutic and curative outcome of chemotherapy in elderly cancer patients aged over 75 years.

Methods: A retrospective study was conducted for elderly cancer patients aged over 75 years who had received more than 2 courses of chemotherapy at our hospital. We analyzed the relationships between RECIST outcome and background factors, such as age, sex, clinical TNM stage, pre-treatment history, ECOG performance status, serum albumin, and Charlson comorbidity index using logistic regression analysis. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-01385-8
Publisher Site
http://dx.doi.org/10.1007/s10147-018-01385-8DOI Listing
January 2019
3 Reads

Optimal maximum duration for delaying salvage operation when recurrence of retroperitoneal liposarcoma is suspected: a single-center study.

Int J Clin Oncol 2019 Jan 2. Epub 2019 Jan 2.

Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, 135-710, Seoul, South Korea.

Background: This study was designed to identify the optimal maximum duration for delaying salvage operation when recurrence of retroperitoneal liposarcoma (LPS) is suspected.

Methods: Patients who underwent salvage operation at Samsung Medical Center for recurrent retroperitoneal LPS from January 2000 to December 2015 were reviewed. The time interval between recurrence and operation for recurrence was divided by 1, 2 or 3 months. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-01383-w
Publisher Site
http://dx.doi.org/10.1007/s10147-018-01383-wDOI Listing
January 2019
1 Read

Preoperative predictive factors focused on inflammation-, nutrition-, and muscle-status in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy.

Int J Clin Oncol 2019 Jan 2. Epub 2019 Jan 2.

Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.

Objective: The present study evaluated the clinical relevance of an integrative preoperative assessment of inflammation-, nutrition-, and muscle-based markers for patients with upper urinary tract urothelial carcinoma (UTUC) undergoing curative nephroureterectomy (NUx).

Methods: The study enrolled 125 patients and the preoperative variables assessed included age, body mass index, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), serum fibrinogen level (Fib), C-reactive protein (CRP), modified Glasgow prognostic score, serum albumin level (Alb), prognostic nutritional index (PNI), skeletal muscle index (SMI), psoas muscle index (PMI), and peak expiratory flow (PEF). The correlations among the variables and their prognostic values after NUx were evaluated. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-01381-y
Publisher Site
http://dx.doi.org/10.1007/s10147-018-01381-yDOI Listing
January 2019
4 Reads

External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.

Int J Clin Oncol 2019 Jan 2. Epub 2019 Jan 2.

Department of Oncology, Military Institute of Medicine, Szaserow 128st, PO Box 04141, 04141, Warsaw, Poland.

Background: We conducted a study to validate the influence of the systemic immune-inflammation index (SII) on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) and to verify whether the implementation of the SII in place of neutrophil and platelet counts within the International Metastatic Renal Cell Carcinoma Consortium (IMDC) model might increase its prognostic accuracy.

Patients And Methods: We retrospectively analyzed consecutive patients with mRCC, who were treated with first-line tyrosine kinase inhibitors from 2008 to 2016 in two major oncology centres in Poland. We stratified patients into low SII (< 730) and high SII (≥ 730) groups according to a recent literature report. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-01390-xDOI Listing
January 2019
1 Read

Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.

Int J Clin Oncol 2019 Jan 2. Epub 2019 Jan 2.

Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Background: Our specific aim was to investigate the prognostic value of effective duration of first androgen deprivation therapy (ADT) and to evaluate the clinical impact on early docetaxel administration with oncological outcomes in castration-resistant prostate cancer (CRPC) patients treated with docetaxel.

Methods: We identified 148 mCRPC patients who were treated with 75 mg/m docetaxel. We defined 16 months as the threshold for the effective duration of ADT, and defined 12 months as the cut-off time for starting docetaxel from the onset of CRPC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-01388-5DOI Listing
January 2019

Risk factors for cardiovascular mortality in patients with colorectal cancer: a population-based study.

Int J Clin Oncol 2019 Jan 2. Epub 2019 Jan 2.

Second Department of Surgery, University General Hospital of Alexandroupoli, Democritus University of Thrace Medical School, 68100, Alexandroupoli, Greece.

Background: Patients with colorectal cancer are at increased risk of cardiovascular mortality compared to the general population. The purpose of this study is to identify risk factors of cardiovascular mortality in patients with colorectal cancer.

Methods: A retrospective review of the Surveillance Epidemiology and End Results (SEER) database was performed between 2010 and 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-01382-xDOI Listing
January 2019

c-D-index is a risk factor for prolonged febrile neutropenia during chemotherapy in patients with acute myeloid leukemia.

Int J Clin Oncol 2019 Jan 2. Epub 2019 Jan 2.

Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, Kagawa, 761-0793, Japan.

Background: D-index is a recently established clinical tool for assessing neutropenia severity. This study examined whether the D-index can predict the onset of various infections in patients with febrile neutropenia (FN).

Methods: We retrospectively investigated FN events in consecutive patients aged < 65 years who were treated for newly diagnosed acute myeloid leukemia at our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-01384-9DOI Listing
January 2019
2 Reads

Clinical target sequencing for precision medicine of breast cancer.

Int J Clin Oncol 2019 Feb 2;24(2):131-140. Epub 2019 Jan 2.

Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, Niigata, 951-8510, Japan.

Precision medicine can be defined as the customization of medical treatment based on the individual genetic profile, which enables one to identify patients who respond to therapies while sparing side effects for those who do not. Breast cancer patients have been treated based on subtyping, which is considered a prototype of precision medicine. Furthermore, the development of multigene panel testing has resulted in a paradigm shift in the treatment of breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-1373-5DOI Listing
February 2019

Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer.

Int J Clin Oncol 2019 Jan 2. Epub 2019 Jan 2.

Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Background: Dose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition. No study has focused on ramucirumab plus modified dose of FOLFIRI for MCRC, and whether low relative dose intensity (RDI) affects treatment efficacy has not been clarified.

Methods: MCRC patients who received ramucirumab plus FOLFIRI, which consisted of 150 mg/m of irinotecan, at six institutions were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-01391-w
Publisher Site
http://dx.doi.org/10.1007/s10147-018-01391-wDOI Listing
January 2019
6 Reads

A multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors.

Int J Clin Oncol 2018 Dec 22. Epub 2018 Dec 22.

Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, Okinawa, Japan.

Background: The aim of this study was to evaluate the effects of treatment with both three-dimensional radiotherapy (3DRT) and weekly 40-mg/m cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors.

Methods: We conducted a retrospective multi-institutional chart review of postoperative uterine cervical cancer patients with high-risk prognostic factors who had been treated with both 3DRT and weekly 40-mg/m cisplatin from 2007 to 2012. Each participating hospital provided detailed information regarding patient characteristics, treatment outcomes, and treatment complications. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-01380-z
Publisher Site
http://dx.doi.org/10.1007/s10147-018-01380-zDOI Listing
December 2018
9 Reads

Interaction of H. pylori with toll-like receptor 2-196 to -174 ins/del polymorphism is associated with gastric cancer susceptibility in southern China.

Int J Clin Oncol 2018 Dec 15. Epub 2018 Dec 15.

Department of Gastroenterology, Changzhou No. 2 People's Hospital, Xinglong Xiang 29, Changzhou, 213000, Jiangsu, China.

Background: Genetic polymorphisms of Toll-like receptors play important roles in gastric carcinogenesis. The aim of this study was to determine the role of TLR2-196 to -174 ins/del polymorphism in gastric cancer susceptibility and prognosis.

Methods: This study included 520 people from southern China. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1379-z
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1379-zDOI Listing
December 2018
1 Read

Knowledge base toward understanding actionable alterations and realizing precision oncology.

Int J Clin Oncol 2019 Feb 12;24(2):123-130. Epub 2018 Dec 12.

Division of Cancer Genome Informatics, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan.

In Japan, the National Cancer Center and university hospitals have initiated next-generation sequencing-based in vitro diagnostic testing for cancer patients as a method of clinical sequencing. Based on the molecular alterations detected, physicians can provide approved targeted therapy and access to investigational drugs for cancer patients. However, interpretation of the clinical significance of genomic alterations remains the most severe bottleneck of precision medicine in cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-1378-0DOI Listing
February 2019

Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer.

Int J Clin Oncol 2018 Nov 30. Epub 2018 Nov 30.

Department of Gynecology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.

Background: Lymphopenia is associated with poor outcomes in patients with various cancers, but little is known about the prognostic impact of lymphopenia in patients with epithelial ovarian cancer (EOC) after induction chemotherapy (IC). This study investigated the prognostic significance of pre- and post-IC lymphopenia in patients with advanced EOC.

Methods: We reviewed medical records of 68 patients with stage III/IV ovarian, fallopian tube, or peritoneal cancer treated with IC at our institution between 2009 and 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-1374-4DOI Listing
November 2018
1 Read

Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.

Int J Clin Oncol 2019 Feb 4;24(2):115-122. Epub 2018 Dec 4.

Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, Niigata, 951-8510, Japan.

Numerous technical and functional advances in next-generation sequencing (NGS) have led to the adoption of this technique in conventional clinical practice. Recently, large-scale genomic research and NGS technological innovation have revealed many more details of somatic and germline mutations in solid tumors. This development is allowing for the classification of tumor type sub-categories based on genetic alterations in solid tumors, and based on this information, new drugs and targeted therapies are being administered to patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-1375-3DOI Listing
February 2019
2 Reads

Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.

Int J Clin Oncol 2018 Dec 4. Epub 2018 Dec 4.

Kyoto University Graduate School of Medicine, Kyoto, Japan.

Background: In PALOMA-2, palbociclib-letrozole significantly improved progression-free survival (PFS) vs placebo-letrozole in women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC) in the first-line setting. We evaluated the efficacy, safety, and pharmacokinetics of palbociclib in Japanese women in PALOMA-2.

Methods: In this phase 3 study, 666 postmenopausal women with ER+/HER2- ABC were randomized 2:1 to palbociclib (125 mg/day [3 weeks on/1 week off]) plus letrozole (2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-1353-9DOI Listing
December 2018
2 Reads

Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites.

Int J Clin Oncol 2018 Nov 24. Epub 2018 Nov 24.

Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.

Background: The management of refractory ascites in advanced ovarian cancer (AOC) is vital for patients with abdominal distention, respiratory distress, and anorexia due to massive ascites with cancer peritonitis. We analyzed the benefits of concentrated ascites reinfusion therapy (CART) in the management of AOC.

Methods: We reviewed records of AOC patients who underwent CART between January 2011 and March 2017. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1371-7
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1371-7DOI Listing
November 2018
12 Reads

Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial.

Int J Clin Oncol 2018 Nov 23. Epub 2018 Nov 23.

Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.

Background: Neoadjuvant chemotherapy (NAC) alone for locally advanced rectal cancer (LARC) remains an experimental treatment, and the efficacy in terms of long-term outcome has not been fully elucidated. The N-SOG 03 trial examined the safety and efficacy of neoadjuvant CAPOX and bevacizumab (Bev) without radiotherapy in patients with poor-risk LARC.

Methods: Thirty-two patients with MRI-defined LARC received neoadjuvant CAPOX and Bev followed by curative resection between 2010 and 2011. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-1372-6DOI Listing
November 2018
6 Reads

Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma.

Int J Clin Oncol 2018 Nov 21. Epub 2018 Nov 21.

Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Background: Despite the clinical benefits of eribulin on overall survival of advanced soft tissue sarcoma (STS) patients, treatment-related toxicity reduces their QOL. Body composition metrics (BCMs) are associated with poor outcome and drug toxicities in several cancers. This study investigated whether BCMs could predict drug toxicity occurrence in advanced STS patients treated with eribulin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-1370-8DOI Listing
November 2018
8 Reads

Histologic transformation of non-small-cell lung cancer in brain metastases.

Int J Clin Oncol 2018 Nov 16. Epub 2018 Nov 16.

Cancer Center, Shandong Provincial Hospital Affiliated to Shandong University, Jingwu Road 324#, Huaiyin District, Jinan, 250021, China.

Background: Treatment strategies differ substantially for small-cell lung cancer (SCLC), adenocarcinoma and squamous-cell cancer (SCC). Therefore, it is of important significance to identify histologic transformation. There are no reports on histologic transformation in brain metastases (BM) to date. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-1369-1DOI Listing
November 2018

Prognostic impact of underlying lung disease in pulmonary wedge resection for lung cancer.

Int J Clin Oncol 2018 Nov 15. Epub 2018 Nov 15.

Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.

Background: Pulmonary wedge resection is an option for lung cancer patients with limited cardiopulmonary preservation. As the impact of underlying lung status on the prognosis of such patients remains unclear, we assessed this issue.

Methods: A total of 149 borderline surgical candidates with localized lung cancer who had undergone wedge resection were retrospectively investigated. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1367-3
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1367-3DOI Listing
November 2018
12 Reads

The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer.

Int J Clin Oncol 2018 Nov 13. Epub 2018 Nov 13.

Department of Otolaryngology, Eiju General Hospital, 2-23-16 Higashiueno, Taito-ku, Tokyo, 110-8645, Japan.

Background: In the treatment of head and neck cancer, severity of chemoradiotherapy-induced oral mucositis has been recognized as one of the key factors affecting the outcomes of the anticancer therapies. Therefore, the development of treatments mitigating oral mucositis would be of clinical significance, although the adequate assessment procedure for efficacy evaluation remains to be established. We conducted this post hoc study to assess the effect of objective evaluation of the severity grade on the outcomes of the clinical trial. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1355-7
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1355-7DOI Listing
November 2018
6 Reads

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).

Int J Clin Oncol 2018 Nov 12. Epub 2018 Nov 12.

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.

Background: Treatment-free remission (TFR), the ability to maintain a molecular response (MR), occurs in approximately 50% of patients with chronic myelogenous leukemia (CML) treated with tyrosine kinase inhibitors (TKIs).

Methods: A multicenter phase 2 trial (Delightedly Overcome CML Expert Stop TKI Trial: DOMEST Trial) was conducted to test the safety and efficacy of discontinuing imatinib. Patients with CML with a sustained MR of 4. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1368-2
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1368-2DOI Listing
November 2018
9 Reads

Genetic association of promoter in GRP78 gene with nasopharyngeal carcinoma in a Chinese population.

Int J Clin Oncol 2018 Nov 9. Epub 2018 Nov 9.

Department of Reproduction and Genetics, the Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.

Background: Emerging evidences were accumulated to support the view that GRP78 might be associated with multiple types of cancer. Given these, the aim of this study is to investigate the relationship between single nucleotide polymorphisms (SNPs) of GRP78 gene promoter and nasopharyngeal carcinoma (NPC).

Methods: Three SNPs (rs3216733, rs17840761 and rs17840762) in GRR78 promoter were estimated in 422 NPC patients and 452 controls. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1366-4
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1366-4DOI Listing
November 2018
5 Reads

Endoscopic sequestrectomy for skull base osteoradionecrosis in nasopharyngeal carcinoma patients: a 10‑year experience.

Int J Clin Oncol 2018 Nov 9. Epub 2018 Nov 9.

Department of Otolaryngology, Eye Ear Nose and Throat Hospital, Shanghai Medical College, Fudan University, 83 Fenyang Road, Shanghai, People's Republic of China.

Background: Skull base osteoradionecrosis is a devastating post-irradiation complication in nasopharyngeal carcinoma patients. We conducted a retrospective analysis to assess the long-term survival and prognostic factors of patients with skull base osteoradionecrosis treated with endoscopic sequestrectomy.

Methods: We enrolled 59 nasopharyngeal carcinoma patients with skull base osteoradionecrosis who underwent endoscopic nasopharyngectomy. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1354-8
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1354-8DOI Listing
November 2018
16 Reads

The effects of intraoperative ICG fluorescence angiography in laparoscopic low anterior resection: a propensity score-matched study.

Int J Clin Oncol 2018 Nov 8. Epub 2018 Nov 8.

Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawara-cho, Sakyo-ku, 606-8507, Kyoto, Japan.

Background: It remains unclear whether indocyanine green (ICG) angiography could reduce the rate of postoperative anastomotic leakage (AL) following rectal surgery. The aim was to determine whether intraoperative ICG angiography could decrease symptomatic AL following laparoscopic low anterior resection (LAR).

Methods: This is a retrospective study of 149 patients with rectal cancer who underwent laparoscopic LAR at a single institution. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1365-5
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1365-5DOI Listing
November 2018
11 Reads

To what extent does the EQ-5D-3L correlate with the FACT-H&N of patients with oral cancer during the perioperative period?

Int J Clin Oncol 2018 Nov 3. Epub 2018 Nov 3.

Department of Health and Welfare Services, National Institute of Public Health, 2-3-6 Minami, Wako, Saitama, 351-0197, Japan.

Background: The EuroQol 5-dimension scale (EQ-5D) is one of the most frequently used preference-based quality of life (QOL) measures for health technology assessment. The 3-level version of the EQ-5D comprises a descriptive system (the EQ-5D-3L) and a visual analog scale (EQ-VAS). It remains unclear whether this five-item scale correlates with the QOL of patients with oral cancer during the perioperative period. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1364-6
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1364-6DOI Listing
November 2018
5 Reads

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.

Int J Clin Oncol 2018 Nov 3. Epub 2018 Nov 3.

Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.

Background: In the double-blind, phase 3 PALOMA-3 study, palbociclib-fulvestrant significantly prolonged progression-free survival versus placebo-fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) whose disease had progressed on prior endocrine therapy. The present study evaluated the efficacy, safety, and pharmacokinetics of palbociclib plus fulvestrant in Japanese patients enrolled in PALOMA-3.

Methods: Pre/peri/postmenopausal women with HR+/HER2- MBC were randomized 2:1 to fulvestrant (500 mg) and either palbociclib (125 mg/day; 3 weeks on/1 week off; n = 347) or placebo (n = 174). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1359-3
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1359-3DOI Listing
November 2018
10 Reads

Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer.

Int J Clin Oncol 2018 Oct 30. Epub 2018 Oct 30.

Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan.

Background: Clinical efficacy of aggressive end-of-life (EOL) chemotherapy remains unclear.

Method: Medical records of patients with advanced cancer between August 2011 and August 2016 were retrospectively analyzed. The primary endpoint was to identify prognostic factors at the last administration of chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-1363-7DOI Listing
October 2018

Verification of the diagnostic strategy for anterior mediastinal tumors.

Int J Clin Oncol 2018 Oct 29. Epub 2018 Oct 29.

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.

Background: For thymic epithelial tumors (TETs), the National Comprehensive Cancer Network guideline has suggested that complete excision of the tumor should be performed without a preoperative biopsy when resectable. However, little evidence has been provided to support this strategy. The purpose of this study was to review our diagnostic process and to evaluate the validity of radical resection of anterior mediastinal masses (AMMs) without pathological confirmation. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1362-8
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1362-8DOI Listing
October 2018
10 Reads

The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.

Int J Clin Oncol 2018 Oct 29. Epub 2018 Oct 29.

Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 80 Vas. Sofias Ave, 115 28, Athens, Greece.

Background: Vascular endothelial growth factor (VEGF) targeting represents the standard first-line therapy for metastatic renal-cell carcinoma (mRCC), while blocking the mammalian target of rapamycin (mTOR) is effective in relapsed disease. Since continuing blockade of VEGF may be of value, we studied the combination of bevacizumab with temsirolimus in mRCC patients relapsing after first-line treatment.

Methods: A prospective, phase II study of the combination of bevacizumab (10 mg/kg, every 2 weeks) with temsirolimus (25 mg weekly) in patients with mRCC who failed first-line anti-VEGF treatment. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1361-9
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1361-9DOI Listing
October 2018
16 Reads

A Japanese survey of malignant disease in pregnancy.

Int J Clin Oncol 2018 Oct 27. Epub 2018 Oct 27.

Department of Obstetrics and Gynecology, Mie University School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan.

Background: In recent years, the incidence of malignant disease in pregnancy has been increasing, but there are few large-scale surveys of malignant disease in pregnancy in Japan. The aim of this study was to survey malignant disease occurring during pregnancy in Japan.

Methods: Malignant disease in pregnancy was defined as diagnosis or treatment for malignant disease, except in situ carcinoma during pregnancy, or within 1-year postpartum. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1352-x
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1352-xDOI Listing
October 2018
9 Reads

Preservation of fertility of adult male cancer patients treated with chemotherapy.

Int J Clin Oncol 2019 Jan 23;24(1):34-40. Epub 2018 Oct 23.

Department of Urology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.

Chemotherapy-induced gonadal dysfunction resulting in transient or persistent infertility depends on the type of drugs and cumulative dose, and it is an important long-term complication, especially for adolescent and young adult (AYA) cancer patients. Due to its importance, a clinical practice guideline for fertility preservation in childhood and AYA cancer patients was published by the Japan Society of Clinical Oncology (JSCO) in 2017. Although the precise mechanisms remain unclear, several studies reported that the cancer itself, not the cancer treatment, adversely affected semen quality. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10147-018-1333-0
Publisher Site
http://dx.doi.org/10.1007/s10147-018-1333-0DOI Listing
January 2019
1 Read